ABIONYX Pharma Statistics
Total Valuation
ABIONYX Pharma has a market cap or net worth of EUR 42.93 million. The enterprise value is 42.45 million.
Market Cap | 42.93M |
Enterprise Value | 42.45M |
Important Dates
The next estimated earnings date is Thursday, September 25, 2025.
Earnings Date | Sep 25, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ABIONYX Pharma has 34.68 million shares outstanding. The number of shares has increased by 14.80% in one year.
Current Share Class | n/a |
Shares Outstanding | 34.68M |
Shares Change (YoY) | +14.80% |
Shares Change (QoQ) | +7.62% |
Owned by Insiders (%) | 32.62% |
Owned by Institutions (%) | 4.73% |
Float | 21.03M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 9.43 |
PB Ratio | 5.71 |
P/TBV Ratio | 20.83 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -9.69 |
EV / Sales | 9.33 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -11.47 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.37.
Current Ratio | 1.58 |
Quick Ratio | 1.49 |
Debt / Equity | 0.37 |
Debt / EBITDA | n/a |
Debt / FCF | -0.74 |
Interest Coverage | -120.68 |
Financial Efficiency
Return on equity (ROE) is -56.76% and return on invested capital (ROIC) is -25.86%.
Return on Equity (ROE) | -56.76% |
Return on Assets (ROA) | -19.67% |
Return on Invested Capital (ROIC) | -25.86% |
Return on Capital Employed (ROCE) | -45.39% |
Revenue Per Employee | 89,235 |
Profits Per Employee | -85,902 |
Employee Count | 51 |
Asset Turnover | 0.32 |
Inventory Turnover | 17.16 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.71% in the last 52 weeks. The beta is 1.02, so ABIONYX Pharma's price volatility has been similar to the market average.
Beta (5Y) | 1.02 |
52-Week Price Change | +12.71% |
50-Day Moving Average | 1.25 |
200-Day Moving Average | 1.26 |
Relative Strength Index (RSI) | 50.35 |
Average Volume (20 Days) | 29,480 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABIONYX Pharma had revenue of EUR 4.55 million and -4.38 million in losses. Loss per share was -0.13.
Revenue | 4.55M |
Gross Profit | 844,000 |
Operating Income | -4.47M |
Pretax Income | -4.38M |
Net Income | -4.38M |
EBITDA | -4.34M |
EBIT | -4.47M |
Loss Per Share | -0.13 |
Balance Sheet
The company has 3.24 million in cash and 2.76 million in debt, giving a net cash position of 478,000 or 0.01 per share.
Cash & Cash Equivalents | 3.24M |
Total Debt | 2.76M |
Net Cash | 478,000 |
Net Cash Per Share | 0.01 |
Equity (Book Value) | 7.52M |
Book Value Per Share | 0.22 |
Working Capital | 2.15M |
Cash Flow
In the last 12 months, operating cash flow was -3.63 million and capital expenditures -68,000, giving a free cash flow of -3.70 million.
Operating Cash Flow | -3.63M |
Capital Expenditures | -68,000 |
Free Cash Flow | -3.70M |
FCF Per Share | -0.11 |
Margins
Gross margin is 18.55%, with operating and profit margins of -98.11% and -96.26%.
Gross Margin | 18.55% |
Operating Margin | -98.11% |
Pretax Margin | -96.26% |
Profit Margin | -96.26% |
EBITDA Margin | -95.36% |
EBIT Margin | -98.11% |
FCF Margin | n/a |
Dividends & Yields
ABIONYX Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -14.80% |
Shareholder Yield | -14.80% |
Earnings Yield | -10.20% |
FCF Yield | -8.62% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ABIONYX Pharma has an Altman Z-Score of 3.01.
Altman Z-Score | 3.01 |
Piotroski F-Score | n/a |